Acasti Pharma Inc. Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Note 15 - Personnel Expenses

Note 15 - Personnel Expenses

12 Months Ended

Mar. 31, 2019

Statement Line Items [Line Items]

Disclosure of personnel expenses [text block

15.

Personnel expenses:

										Thirteen- months ended				Month ended				Twelve-month period ended
		March 31, 2019				March 31, 2018				March 31, 2017				March 31, 2017 (Unaudited)				February 28, 2017 (Unaudited)
		$				$				$				$				$
Salaries and other short-term employee benefits			4,144				3,281				2,491				214				2,277
Share-based compensation costs			1,041				929				674				86				588
Total personnel expenses			5,185				4,210				3,165				300				2,865